Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. [PDF]
Arch RheumatolBakay U, İzci Duran T.
europepmc +1 more source
The impact of nurse-led disease management education on outcomes of patients with ankylosing spondylitis: a randomised controlled trial. [PDF]
J Res NursDağ A, Tulek Z, Seyahi E.
europepmc +1 more source
Erosive costovertebral joint arthritis as a novel feature of ankylosing spondylitis. [PDF]
Quant Imaging Med SurgZhang S, Dai X, Xu S, Wang Q, Wang S.
europepmc +1 more source
Efficacy of Tofacitinib in Refractory Axial Spondylarthritis: A Dose-Escalation Study. [PDF]
CureusTazbir AM +7 more
europepmc +1 more source
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years. [PDF]
Arthritis Res TherRamiro S +10 more
europepmc +1 more source
Underestimation of fracture risk by conventional FRAX thresholds in axial spondyloarthritis: a proposal for disease-specific thresholds. [PDF]
Ther Adv Musculoskelet DisChaiamnuay S, Harirattanakul A.
europepmc +1 more source
Correlation Between Serum Procalcitonin and Disease Activity Score in Patients with Ankylosing Spondylitis That Have Hip Involvement. [PDF]
Int J Gen MedLiang X, Deng B.
europepmc +1 more source
Body composition, bone mineral density, and functional impairment in axial spondyloarthritis: a 36-month longitudinal study. [PDF]
BMC Musculoskelet DisordCeolin C +9 more
europepmc +1 more source
Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. [PDF]
Rheumatology (Oxford)Moldovan DMM +10 more
europepmc +1 more source
Minimal seasonal variation in disease parameters of axial spondyloarthritis: a register-based study. [PDF]
Rheumatol IntOnkamo E, Sundström B, Wahlin B.
europepmc +1 more source